# DAVITA INC. (DVA) FY2026 Q3 Revenue by Health Care Revenue Source

- Company: DAVITA INC. (DVA)
- Statement: DAVITA INC. (DVA) FY2026 Q3 P&L / Income Statement, https://plicit.ai/financials/dva/fy2026-q3-income-statement
- Period: 2026-07-01 to 2026-09-30
- Filing: Q3 FY2026 10-Q, filed 2026-10-29, accession number 0000927066-26-000134
- Page: https://plicit.ai/financials/dva/fy2026-q3-income-statement/revenue-by-health-care-revenue-source
- Chart image: https://plicit.ai/charts/dva-fy2026-q3-revenue-by-health-care-revenue-source-sankey.png

## Chart details: Revenue by Health Care Revenue Source

Income statement for 2026-07-01 through 2026-09-30. View: Health Care Organization, Revenue Sources. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

- **Total revenues**: 3,578,126,000 US dollars
- **Total operating expenses**: 3,078,871,000 US dollars
- **Operating income**: 499,255,000 US dollars
- **Other income (expense), net (calculated)**: negative 140,548,000 US dollars
- **Income before income taxes**: 358,707,000 US dollars
- **Income tax expense**: 89,318,000 US dollars
- **Net income**: 269,389,000 US dollars
- **Medicare and Medicare Advantage**: 1,756,098,000 US dollars
- **Medicaid and Managed Medicaid**: 228,173,000 US dollars
- **Other Government Payors**: 342,647,000 US dollars
- **Commercial Payors**: 1,103,356,000 US dollars
- **Undisclosed (calculated)**: 147,852,000 US dollars
- **Patient care costs**: 2,451,047,000 US dollars
- **General and administrative**: 408,697,000 US dollars
- **Depreciation and amortization**: 165,188,000 US dollars
- **Equity investment income, net**: negative 8,237,000 US dollars
- **Goodwill and other asset impairment charges**: 62,176,000 US dollars

### Chart connections

- Revenue minus operating expenses equals operating income.
- Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.
- Of which attributable to DAVITA INC.: $222.93 M; to noncontrolling interests: $46.46 M.

## Key Takeaways

- Medicare and Medicare Advantage brought in $1.76 B, 49% of revenue, but grew only 2.4%.
- Commercial payors grew 4.5% to $1.10 B and supplied 30% of the $157.90 M revenue rise.
- Normalized U.S. treatment growth, excluding acquisitions, was just 0.4% from a year earlier.
- Management credits year-to-date gains in revenue per treatment to Medicare base rate increases.

## The Unvarnished Truth

### DaVita's dialysis growth is price, not patients, with volumes up 0.4%

DaVita's dialysis business is barely adding patients. Normalized U.S. treatment growth, which strips out acquisitions, was just 0.4% from a year earlier. Yet revenue rose 4.6% to $3.58 B. The payer split shows who paid for that: Medicare and Medicare Advantage brought in $1.76 B, up only 2.4%, while commercial payors grew 4.5% to $1.10 B and Medicaid 6.3%. Commercial insurers supplied 30% of the $157.90 M rise in revenue. So growth leans on price and on payers outside Medicare, not on more people in chairs.

Why does the mix matter? Management says year-to-date revenue per treatment rose mainly on Medicare base rate and other annual rate increases, partially offset by unfavorable changes in payor mix. This quarter, revenue per treatment dipped from the second quarter, which management puts down to normal fluctuations. Medicare and Medicare Advantage still made up 49% of revenue, against 50% a year earlier. With the largest payer group setting its own base rate, DaVita's growth rides on each annual update. Volume, the lever it controls, has stalled.

For investors, the question is how long price can carry a business whose patient volumes barely grow. Medicaid and Managed Medicaid grew fastest, up 6.3%, but at $228.17 M it is small. Commercial payors, the second-largest source at 31% of revenue, decide most of the upside. Outside patient care, other revenues jumped 39% to $169.86 M, a sideline rather than a fix. Watch normalized treatment growth and the payer mix in each quarter's filing. If volumes stay flat and Medicare's rate updates slow, where does DaVita's next dollar of growth come from?

## Intelligent Insights for Investors

### How much does DaVita depend on its biggest group of payers?

Heavily: Medicare and Medicare Advantage brought in 49% of revenue this quarter, against 31% for commercial payors, the next largest.

### Which payers drove the change in DaVita's sales over the past year?

The biggest push came from commercial payors, which grew 4.5% and supplied 30% of the rise in revenue this quarter. The rest of the rise came from other payers.

### Which payer group lost the most ground over the past year?

None of the payer groups shrank. Medicare and Medicare Advantage gained least: it grew 2.4% from a year earlier, against 4.6% for revenue as a whole.

## Intelligent Insights for Employees

### Which payer group grew fastest over the past year?

Medicaid and Managed Medicaid: up 6.3% this quarter, against 4.6% for revenue as a whole.

## Intelligent Insights for Everyone

### How has the mix of DaVita's payers shifted over the past year?

Hardly: Medicare and Medicare Advantage, the largest, made up 49% of revenue this quarter, against 50% a year earlier.
